Femasys Inc. (FEMY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 3, 2025, discloses that Femasys Inc. (the "Company") has entered into a Material Definitive Agreement for a private placement of securities. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Suwanee, Georgia. The filing details a capital raise intended to refinance existing debt and fund working capital.
Key Financial Metrics and Transaction Details
The Company agreed to sell securities to accredited investors with the following terms:
- Total Gross Proceeds: Expected to be $12,000,000.
- Debt Instrument: Senior secured convertible notes with an aggregate principal amount of approximately $12,000,000 (split between two closings).
- Interest Rate: 8.50% per annum, payable annually in-kind (PIK).
- Maturity: Ten years from the date of issuance.
- Conversion Price: $0.73 per share (representing a 15% premium to the closing price prior to the agreement).
- Warrants Issued:
- Series A-1: Exercise price of $0.81 per share.
- Series B-1: Exercise price of $0.92 per share.
- Series C-1: Exercise price of $1.10 per share.
- Insider Participation: Company insiders (CEO, CFO, and a Board member) purchased approximately $100,000 of securities on identical terms.
Material Changes and Use of Proceeds
The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the current period versus the prior period. The primary material change is the execution of the Securities Purchase Agreement. The Company intends to use the net proceeds to:
- Repay in full the senior convertible notes issued in November 2023 by their stated maturity.
- Fund working capital and other general corporate purposes.
Guidance, Risks, and Contingencies
Management Commentary and Governance:
- The Lead Lender (Pointillist Global Macro Series of Pointillist Partners LLC) has the right to nominate one director to the Board until the earlier of the Lead Lender owning less than 4.99% of outstanding shares, full repayment of Notes, or the five-year anniversary of the First Closing Date.
- Following the five-year anniversary, the Lead Lender may designate a non-voting observer.
- The Lead Lender has agreed to a standstill preventing beneficial ownership exceeding 30% of outstanding Common Stock for five years.
Risks and Contingencies:
- Dilution Cap: Conversion of Notes or exercise of Warrants is prohibited if it results in the issuance of more than 19.99% of outstanding Common Stock unless stockholder approval is obtained. The Company intends to seek this approval at its next annual meeting, but there is no assurance it will be granted.
- Events of Default: Include failure to file/maintain an effective registration statement or failure to pay amounts due. Upon default, holders may require redemption of Notes at 100% of the Conversion Amount.
- Warrant Expiration Triggers: Series B-1 Warrants expire early if the Company reports two consecutive quarters of $3.25 million in sales. Series C-1 Warrants expire early if the Company receives FDA approval for FemBloc Permanent Birth Control.
- Liquidity: There is no established public trading market for the Notes or Warrants.
Investor Verification Checklist
- Verify the effectiveness of the resale registration statement required to be filed within six months of the First Closing Date.
- Confirm the status of the November 2023 senior convertible notes and the timeline for their repayment.
- Monitor the Company's progress toward obtaining stockholder approval for issuances exceeding the 19.99% dilution threshold.
- Review the Company's cash position to ensure it can meet the 8.50% PIK interest obligations and other covenants.
- Assess the impact of the Lead Lender's board seat and standstill provisions on future corporate governance and M&A flexibility.